Abeona Therapeutics Inc (ABEO) - Total Liabilities
Based on the latest financial reports, Abeona Therapeutics Inc (ABEO) has total liabilities worth $60.35 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Abeona Therapeutics Inc - Total Liabilities Trend (1995–2025)
This chart illustrates how Abeona Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See ABEO net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Abeona Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Abeona Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MCNEX Co. Ltd
KQ:097520
|
Korea | ₩221.01 Billion |
|
Cartesian Growth Corporation III Class A Ordinary Shares
NASDAQ:CGCT
|
USA | $13.54 Million |
|
SDT Uzay ve Savunma Teknolojileri A.S.
IS:SDTTR
|
Turkey | TL1.56 Billion |
|
Hung Ching Development & Construction Co Ltd
TW:2527
|
Taiwan | NT$14.47 Billion |
|
American Integrity Insurance Group, Inc.
NYSE:AII
|
USA | $888.05 Million |
|
ZKH Group Limited
NYSE:ZKH
|
USA | $3.36 Billion |
|
UD Electronic
TWO:3689
|
Taiwan | NT$1.93 Billion |
|
Amazing Microelectronic
TWO:6411
|
Taiwan | NT$1.31 Billion |
Liability Composition Analysis (1995–2025)
This chart breaks down Abeona Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Abeona Therapeutics Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Abeona Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Abeona Therapeutics Inc (1995–2025)
The table below shows the annual total liabilities of Abeona Therapeutics Inc from 1995 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $60.35 Million | -7.00% |
| 2024-12-31 | $64.90 Million | +31.97% |
| 2023-12-31 | $49.18 Million | +31.30% |
| 2022-12-31 | $37.45 Million | +0.63% |
| 2021-12-31 | $37.22 Million | -23.49% |
| 2020-12-31 | $48.65 Million | +8.22% |
| 2019-12-31 | $44.95 Million | +11.39% |
| 2018-12-31 | $40.35 Million | +365.55% |
| 2017-12-31 | $8.67 Million | -27.53% |
| 2016-12-31 | $11.96 Million | -3.03% |
| 2015-12-31 | $12.33 Million | +4.83% |
| 2014-12-31 | $11.77 Million | -23.56% |
| 2013-12-31 | $15.39 Million | -18.15% |
| 2012-12-31 | $18.81 Million | -12.08% |
| 2011-12-31 | $21.39 Million | -27.65% |
| 2010-12-31 | $29.57 Million | +3.48% |
| 2009-12-31 | $28.57 Million | +86.05% |
| 2008-12-31 | $15.36 Million | +81.35% |
| 2007-12-31 | $8.47 Million | -48.09% |
| 2006-12-31 | $16.31 Million | +42.47% |
| 2005-12-31 | $11.45 Million | -35.50% |
| 2004-12-31 | $17.75 Million | +0.65% |
| 2003-12-31 | $17.64 Million | -7.17% |
| 2002-12-31 | $19.00 Million | +15.78% |
| 2001-12-31 | $16.41 Million | +5.71% |
| 2000-12-31 | $15.52 Million | +1452.20% |
| 1999-12-31 | $1.00 Million | +66.67% |
| 1998-12-31 | $600.00K | -29.25% |
| 1997-12-31 | $848.00K | -2.30% |
| 1996-12-31 | $868.00K | +95.94% |
| 1995-12-31 | $443.00K | -- |
About Abeona Therapeutics Inc
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of starga… Read more